GC Cell Blood Cancer Treatment Achieves Complete Remission in Phase 1 Trial

[Financial News] GC Cell's blood cancer treatment candidate GCC2005 showed a treatment response in five of eight patients in an early-stage clinical trial. Three of them achieved complete remission, with no cancer detected in examinations.
GC Cell announced on the 21st that it had presented interim results from the Phase 1a trial of GCC2005 in patients with relapsed or refractory NK/T-cell lymphoma at ICBMT 2026, held at BEXCO in Busan on the 17th.
As of October 31 last year, a total of nine patients had been enrolled in the trial. Among the eight patients whose tumor status could be evaluated after treatment, the objective response rate (ORR) was 62.5%. The objective response rate is the percentage of patients whose tumors shrink or disappear after treatment. Three patients achieved complete remission (CR), with no cancer observed, while two achieved partial remission (PR), in which tumors shrank by at least a certain amount.
There were also cases in which the treatment effect was sustained over the long term. A patient with angioimmunoblastic T-cell lymphoma (AITL), who had relapsed after receiving three prior treatments, achieved complete remission after receiving GCC2005 and has maintained that status for 18 months. Another patient had a large tumor before treatment but achieved complete remission after the tumor disappeared within a short period following treatment.
In the initial safety assessment, neither immune effector cell-associated neurotoxicity syndrome (ICANS), a neurological adverse event that can occur with immune cell therapies, nor graft-versus-host disease (GvHD) was reported.
GCC2005 is an NK-cell-based treatment designed to identify and attack CD5, a protein found on the surface of cancer cells. NK cells are immune cells that can directly attack cancer cells, and GCC2005 uses NK cells obtained from healthy individuals to create the treatment. GC Cell is developing it as a new treatment for patients with relapsed or refractory blood cancers.
The conference also presented the rationale behind designing GCC2005 to target CD5, along with results from cell-based experiments and animal studies.
GC Cell has completed patient dosing in its domestic Phase 1a trial and is preparing to enter Phase 1b. It previously presented GCC2005 clinical results at major international conferences, including the American Society of Hematology (ASH).
Yoon Deok-hyun, a professor of medical oncology at Asan Medical Center, said, "Relapsed or refractory T-cell lymphoma is a difficult-to-treat disease with limited treatment options after multiple rounds of therapy. Further clinical trials are needed to more specifically confirm GCC2005's therapeutic potential."
Won Sung-yong, CEO of GC Cell, said, "We are continuously sharing GCC2005's clinical achievements through major international conferences. We will proceed with the Phase 1b trial without setbacks and continue its development toward global registrational trials."
[email protected] Jeong Sang-hee Reporter